JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis
Wang, Lin; Huang, Xin-En; Ji, Zhu-Qing; Liu, Meng-Yan; Qian, Ting; Li, Li;
  PDF(new window)
 Abstract
Objective: To assess the safety and effectiveness of a mouth-rinse with G-CSF (JiSaiXin, produced by NCPC Biotechnology Co., Ltd) in treating patients with chemotherapy-induced oral mucositis (CIM). Method: A consecutive cohort of patients with advanced cancers and CIM were treated with mouth-rinse G-CSF. All chemotherapy for patients with advanced cancers was adopted from regimens suggested by NCCN guidelines. The mouth-rinse with G-CSF at a dose of 150-300ug plus 100ml-500ml normal saline was started from the time of oral mucositis was confirmed and continuously used for at least 7 days as one course. After at least two courses of treatment, safety and efficacy were evaluated. Results: There were 7 female and 7 male patients with advanced cancer and CIM recruited into this study, including 5 with colorectal, 2 with lung, 1 patient with gastric, 1 with cervical and 1 with pancreatic cancer, as well as 2 patients with diffuse large B cell lymphomas, 1 with nasopharyngeal and 1 with gastric cancer. The median age was 57 (41-79) years. Grade 1 to 2 myelosuppression was observed in 3/14 patients, and Grade 4 myelosuppression in 1/14. Adverse effects on the gastrointestinal tract were documented in 5/14 patients, and were Grade 1 to Grade 3. No treatment related death was documented. Regarding CIM, the median response time to mouth rinse of G-CSF was 2 (1-5) days, and all patients with CIM demonstrated a positive response. Conclusions: Mouth-rinse with G-CSF proved to be safe and effective in treating patients with advanced cancers and CIM. However, further randomized controlled studies should be conducted to clarify the effectiveness of this treatment with other lesions.
 Keywords
Mouth-rinse with G-CSF;chemotherapy induced oral mucositis;
 Language
English
 Cited by
 References
1.
Abitbol AA, Sridhar KS, Lewin AA, et al (1997). Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Cancer, 80, 266-76. crossref(new window)

2.
Bez C, Demarosi F, Sardella A, et al (1999). GM-CSF mouthrinses in the treatment of severe oral mucositis: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 88, 311-5 crossref(new window)

3.
Cao J, Huang XE, Liu J, et al (2014). Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev, 14, 7171-7.

4.
Cartee L, Petros WP, Rosner GL, et al (1995). Evaluation of GMCSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine, 7, 471-7. crossref(new window)

5.
chemotherapy-induced oral mucositis. Surg Today, 25, 202-6.

6.
Chen YS, Xu SX, Ding YB, et al (2014). Colorectal cancer screening in high-risk populations: a survey of cognition among medical professionals in Jiangsu, China. Asian Pac J Cancer Prev, 14, 6487-91.

7.
Chen YS, Xu SX, Ding YB, et al (2014). Helicobacter pylori Infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. Asian Pac J Cancer Prev, 14, 7613-9.

8.
Chi KH, Chen CH, Chan WK, et al (1995). Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol, 13, 2620-8.

9.
Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. crossref(new window)

10.
Cui L, Sun YH, Chen J, et al (2015). Analysis of Prethrombotic States in Patients with Malignant Tumors. Asian Pac J Cancer Prev, 16, 5477-82. crossref(new window)

11.
Dazzi C, Cariello A, Giovanis P, et al (2003). Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann Oncol, 14, 559-63. crossref(new window)

12.
Hejna M, Kostler WJ, Raderer M, et al (2001). Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial. Eur J Cancer, 37, 1994-2002 crossref(new window)

13.
Huang XE, Cao J, Qian ZY, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev, 15, 8495-7. crossref(new window)

14.
Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.

15.
Huang XE, Wang L, Ji ZQ, et al (2015). Safety of Lienal Polypeptide Injection Combined with Chemotherapy in Treating Patients with Advanced Cancer. Asian Pac J Cancer Prev, 16, 7837-41. crossref(new window)

16.
Huang XE, Yan XC, Wang L, et al (2015). Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer. Asian Pac J Cancer Prev, 16, 7867-9. crossref(new window)

17.
Ibrahim EM, al-Mulhim FA (1997). Effect of granulocytemacrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients. Med Oncol, 14, 47-51 crossref(new window)

18.
Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. crossref(new window)

19.
Jyung RW, Wu L, Pierce GF, et al (1994). Granulocytemacrophage colony-stimulating factor and granulocyte colony-stimulating factor: differential action on incisional wound healing. Surgery, 115, 325-34.

20.
Kalyanaraman B, Joseph J, Kalivendi S, et al (2002). Doxorubicininduced apoptosis: implications in cardiotoxicity. Mol Cell Biochem, 234-5, 119-24. crossref(new window)

21.
Kannan V, Bapsy PP, Anantha N, et al (1997). Efficacy and safety of granulocyte macrophage-colony stimulating factor (GMCSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiat Oncol Biol Phys, 37, 1005-10. crossref(new window)

22.
Karthaus M, Rosenthal C, Huebner G, et al (1998). Effect of topical oral G-CSF on oral mucositis: a randomised placebocontrolled trial. Bone Marrow Transplant, 22, 781-785 crossref(new window)

23.
Katano M, Nakamura M, Matsuo T, et al (1995)..Effect of granulocyte colony-stimulating factor (G-CSF) on

24.
Li Y, Huang XE (2015). A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Nonsmall-cell Lung Cancer. Asian Pac J Cancer Prev, 16, 4797-800. crossref(new window)

25.
Liu J, Huang XE (2015). Clinical application of serum tumor abnormal protein from patients with gastric cancer. Asian Pac J Cancer Prev, 16, 4041-4. crossref(new window)

26.
Liu J, Huang XE l (2014). Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac J Cancer Prev, 15, 10241-4.

27.
Liu J, Huang XE, Feng JF (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90. crossref(new window)

28.
Liu MY, Huang XE (2015). Effects of analgecine on oxaliplatininduced neurotoxicity in patients with gastrointestinal cancer. Asian Pac J Cancer Prev, 16, 4465-8. crossref(new window)

29.
Loprinzi C, Gastineau D, Foote R (1995). Oral complications Clinical Oncology . New York: Churchill Livingstone, pp. 741-54.

30.
Lu YY, Huang XE, Wu XY, et al (2014). Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Asian Pac J Cancer Prev, 15, 3335-41. crossref(new window)

31.
Makkonen TA, Minn H, Jekunen A, et al (2000). Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. Int J Radiat Oncol Biol Phys, 46, 525-534. crossref(new window)

32.
Mantovani G, Massa E, Astara G, et al (2003). Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapyinduced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncol Rep, 10, 197-206

33.
Mascarin M, Franchin G, Minatel E, et al (1999). The effect of granulocyte colonystimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol, 35, 203-208. crossref(new window)

34.
McAleese JJ, Bishop KM, A'Hern R, et al (2006). Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. Br J Radiol, 79, 608-13 crossref(new window)

35.
McGuire DB, Fulton JS, Park J, et al (2013). Systematic review of basic oral care for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21, 3165-77. crossref(new window)

36.
Mosel D, Bauer R, Lynch D, et al (2011). Oral complications in the treatment of cancer patients. Oral Dis, 17, 550-9. crossref(new window)

37.
Naumov GN, Townson JL, MacDonald IC, et al (2003). Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat, 82, 199-206. crossref(new window)

38.
Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, et al (1998). A pilot study of the effect of granulocyte-macrophage colonystimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report. Int J Radiat Oncol Biol Phys, 42, 551-6 crossref(new window)

39.
Nicolatou-Galitis O, Dardoufas K, Markoulatos P, et al (2001). Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colonystimulating factor (GM-CSF) mouthwash. J Oral Pathol Med, 8, 471-80.

40.
Nicolatou-Galitis O, Sarri T, Bowen J, et al (2013). Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Supportive Care in Cancer, 21, 3179-89. crossref(new window)

41.
Patte C, Laplanche A, Bertozzi AI, et al (2002). Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. J Clin Oncol, 20, 441-448. crossref(new window)

42.
Plevova P (1999). Prevention and treatment of chemotherapyand radiotherapy-induced oral mucositis: a review. Oral Oncol, 35, 453-70. crossref(new window)

43.
Qian T, Huang XE (2015). Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers. Asian Pac J Cancer Prev, 16, 4791-5. crossref(new window)

44.
Qian YD, Xu X, Wang L, Huang XE (2014). Clinical safety of chemotherapy for elderly cancer patients complicated with hypertension. Asian Pac J Cancer Prev, 15, 9875-7. crossref(new window)

45.
Raber-Durlacher J, Weijl N, Saris MA, et al (2000). Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer, 8, 366-71. crossref(new window)

46.
Raber-Durlacher JE, von Bultzingslowen I, Logan RM, et al (2013). Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer, 21, 343-55. crossref(new window)

47.
Rosso M, Blasi G, Gherlone E, et al (1997). Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemoradiotherapy. J Chemother, 9, 382-5. crossref(new window)

48.
Rovirosa A, Ferre J, Biete A (1998). Granulocyte macrophagecolony-stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. Int J Radiat Oncol Biol Phys, 41, 747-54. crossref(new window)

49.
Ryu JK, Swann S, LeVeque F, et al (2007). The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. Int J Radiat Oncol Biol Phys, 67, 643-50. crossref(new window)

50.
Saarilahti K, Kajanti M, Joensuu T, et al (2002). Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiationinduced mucositis: a double-blind prospective randomized phase III study. Int J Radiat Oncol Biol Phys, 54, 479-85 crossref(new window)

51.
Saunders DP, Epstein JB, Elad S, et al (2013). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer, 21, 3191-207. crossref(new window)

52.
Schneider SB, Nishimura RD, Zimmerman RP, et al (1999). Filgrastim (rmetHuG-CSF) and its potential use in the reduction of radiationinduced oropharyngeal mucositis: an interim look at a randomized, double-blind, placebocontrolled trial. Cytokines Cell Mol Ther, 5, 175-80.

53.
Shen K, Huang XE (2015). Clinical investigation in effect of riboflavin sodium phosphate on prevention and treatment for patients with radiotherapy related esophagitis. Asian Pac J Cancer Prev, 16, 1525-7. crossref(new window)

54.
Shi B, Zhang XB, Xu J, et al (2015). Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev, 16, 5521-4. crossref(new window)

55.
StokmanMA, Spijkervet FK, Boezen HM, et al (2006). Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of metaanalyses. J Dent Res, 85, 690-700 crossref(new window)

56.
Su YB, Vickers AJ, Zelefsky MJ, et al (2006). Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Cancer J, 12, 182-8. crossref(new window)

57.
Sun YH, Cui L, Chen J, et al (2015). Analysis of Relationships Between Prethrombotic States and Cervical Cancer. Asian Pac J Cancer Prev, 16, 6163-6. crossref(new window)

58.
Tian GY, Miu M, Huang XE (2014). Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev, 15, 8475-8. crossref(new window)

59.
Valcarcel D, Sanz MA Jr, Sureda A, et al (2002). Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study. Bone Marrow Transplant, 29, 783-7 crossref(new window)

60.
van der Lelie H, Thomas BL, van Oers RH, et al (2001). Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled doubleblind study. Ann Hematol, 80, 150-4 crossref(new window)

61.
Viens P, Gravis G, Bladou F, et al (1996). Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma. Eur Cytokine Netw, 7, 395-9.

62.
Wagner W, Alfrink M, Haus U, et al (1999). Treatment of irradiation-induced mucositis with growth factors (rhGMCSF) in patients with head and neck cancer. Anticancer Res, 19, 799-803.

63.
Wang L, Huang XE (2015). Clinical study on safety and efficacy of JiSaiXin (recombinant human granulocyte colony stimulating factor injection manufactured in China) for Chinese undergoing chemotherapy. Asian Pac J Cancer Prev, 16, 299-301. crossref(new window)

64.
Wang L, Huang XE, Cao J (2014). Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. Asian Pac J Cancer Prev, 15, 5597-600. crossref(new window)

65.
Worthington HV, Clarkson JE, Bryan G, et al (2010). Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev (12): CD000978

66.
Wu XY, Huang XE (2015). Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients. Asian Pac J Cancer Prev, 16, 3425-8. crossref(new window)

67.
Wu XY, Huang XE (2015). Screening for patients with non-small cell lung cancer who could survive long term chemotherapy. Asian Pac J Cancer Prev, 16, 647-52. crossref(new window)

68.
Wu XY, Huang XE, Cao J, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4. crossref(new window)

69.
Xiao Y, Liu J, Huang XE, et al (2014). Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Asian Pac J Cancer Prev, 15, 10445-9.

70.
Xiao Y, Liu J, Liu YC, et al (2014). Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Asian Pac J Cancer Prev, 15, 3951-4. crossref(new window)

71.
Xu C, Huang XE, Lv PH, et al (2015). Radiofrequency Ablation in Treating Colorectal Cancer Patients with Liver Metastases. Asian Pac J Cancer Prev, 16, 8559-61.

72.
Xu C, Huang XE, Wang SX, et al (2014). Drainage alone or combined with anti-tumor therapy for treatment of obstructive jaundice caused by recurrence and metastasis after primary tumor resection. Asian Pac J Cancer Prev, 15, 2681-4. crossref(new window)

73.
Xu C, Huang XE, Wang SX, et al (2015). Comparison of infection between internal-external and external percutaneous transhepatic biliary drainage in treating patients with malignant obstructive jaundice. Asian Pac J Cancer Prev, 16, 2543-6. crossref(new window)

74.
Xu C, Lv PH, Huang XE, et al (2014). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6. crossref(new window)

75.
Xu C, Lv PH, Huang XE, et al (2014). Analysis of different ways of drainage for obstructive jaundice caused by hilar cholangiocarcinoma. Asian Pac J Cancer Prev, 15, 5617-20. crossref(new window)

76.
Xu C, Lv PH, Huang XE, et al (2014). Internal-external percutaneous transhepatic biliary drainage for patients with malignant obstructive jaundice. Asian Pac J Cancer Prev, 15, 9391-4. crossref(new window)

77.
Xu C, Lv PH, Huang XE, et al (2015). Efficacy of Transarterial Chemoembolization Combined with Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma. Asian Pac J Cancer Prev, 16, 6159-62. crossref(new window)

78.
Xu C, Lv PH, Huang XE, et al (2015). Radiofrequency Ablation for Liver Metastases after Transarterial Chemoembolization: A Systemic Analysis. Asian Pac J Cancer Prev, 16, 5101-6. crossref(new window)

79.
Yang L, Sun Y, Huang XE, et al (2015). Carcinoma microsatellite instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for stage II rectal cancer. Asian Pac J Cancer Prev, 16, 1545-51. crossref(new window)

80.
Zhou SB, Liu YC, Yin XX, et al (2015). Clinical observation of three dimensional conformal radiotherapy with tamoxifen in treatment of postoperative malignant glioma. Asian Pac J Cancer Prev, 16, 1743-5. crossref(new window)